JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
CHALLENGING THE PARADIGMS IN B-CELL MALIGNANCIES
Co-Chairs: M. Dreyling, Munich (Germany) and S. Rule, Plymouth (UK)
WELCOME AND INTRODUCTION
M. Dreyling, Munich (Germany)
LEVERAGING THE B-CELL SIGNALLING PATHWAYS
M. Dreyling, Munich (Germany)
APPLYING BIOLOGICAL INSIGHTS TO THE CLINICAL MANAGEMENT OF MANTLE CELL LYMPHOMA
M.L. Wang, Houston, TX (USA)
PANEL DISCUSSION
All
INTEGRATING NOVEL THERAPIES INTO THE PRACTICAL MANAGEMENT OF PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA
S. Treon, Boston, MA (USA)
THE BIOLOGIC BASIS FOR IMPROVED CLINICAL MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
S. Stilgenbauer, Ulm (Germany)
PANEL DISCUSSION
All
Wednesday, June 17, from 19:00 to 21:00 (room B)
GILEAD SCIENCES EUROPE, LTD.
NEW OPTIONS AND EVOLVING STRATEGIES IN THE MANAGEMENT OF HEMATOLOGICAL MALIGNANCIES
Co-Chairs: M. Hallek, Cologne (Germany) and G. Salles, Lyon (France)
INTRODUCTION: A REVIEW OF THE CURRENT LANDSCAPE IN HEMATOLOGICAL MALIGNANCIES
G. Salles, Lyon (France)
NOVEL TARGETED THERAPIES IN DIFFICULT-TO-TREAT CLL
M. Hallek, Cologne (Germany)
CRITICAL CASES IN CLL—APPLYING THE LATEST KNOWLEDGE TO SPECIFIC SCENARIOS
B. Eichhorst, Cologne (Germany)
TREATMENT STRATEGIES FOR PROLONGED CARE—OPTIONS AND SEQUENCING IN RELAPSED iNHL
G. Salles, Lyon (France)
CRITICAL CASES IN iNHL—APPLYING THE LATEST KNOWLEDGE TO SPECIFIC SCENARIOS
A. Davies, Southampton (UK)
LOOKING FORWARD: THE EVOLVING TREATMENT PARADIGM IN CLL AND FL
M. Dreyling, Munich (Germany)
OPEN Q&A BASED ON DISCUSSIONS FROM THE PRESENTATIONS
All, led by Co-Chairs
SUMMARY AND CLOSE
M. Hallek, Cologne (Germany)
Thursday, June 18, from 19:00 to 21:00 (room A)
CELGENE CORPORATION
IMMUNE-BASED STRATEGIES TOWARDS ADVANCING THE TREATMENT OF B-CELL MALIGNANCIES
Chair: F. Cavalli, Bellinzona (Switzerland)
WELCOME AND INTRODUCTION
F. Cavalli, Bellinzona (Switzerland)
THE QUEST FOR ENDPOINTS IN GUIDING TREATMENT DECISIONS IN FOLLICULAR LYMPHOMA
N. Fowler, Houston, TX (USA)
NEW APPROACHES TO THE TREATMENT OF FOLLICULAR LYMPHOMA
B.D. Cheson, Washington, DC (USA)
OPTIMIZING TREATMENT OF RELAPSED AND/OR REFRACTORY MANTLE CELL LYMPHOMA
M. Trněný, Prague (Czech Republic)
IMPROVING ON FRONTLINE OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA
U. Vitolo, Turin (Italy)
ADVANCEMENT IN OUR UNDERSTANDING OF IMMUNOMODULATING AGENTS IN B-CELL MALIGNANCIES
J.G. Gribben, London (UK)
CLOSING REMARKS
F. Cavalli, Bellinzona (Switzerland)
Immune-based strategies towards advancing the treatment of B-cell malignancies
B-cell lymphomas make up approximately 85% of non-Hodgkin lymphomas (NHLs) and, despite the emergence of novel therapies, optimization of treatment for patients with lymphoma still requires further attention [1-3]. The development of novel therapies will help fulfil the unmet needs of patients with NHL, which include treatment toxicities, frequent relapses, and emergence of therapeutic resistance.
Several pathways that play key roles in the development of B-cell malignancies have been identified [4]. We are also gaining an increasing understanding of how non-malignant effector cells in the immune microenvironment contribute to tumor cell survival and proliferation, and the emergence of therapeutic resistance. These new insights, combined with streamlined advances in medicinal chemistry, have moved treatment approaches away from traditional chemotherapy. A deeper understanding of tumorigenic mechanisms has resulted in the development of non-chemotoxic treatments. Such treatments include the use of tyrosine kinase inhibitors (TKIs), which specifically inhibit the deregulated activity of individual molecules in the signal transduction cascade, as well as immunomodulatory agents and checkpoint inhibitors. Immune-based approaches alter microenvironmental mechanisms, thus preventing tumors from developing immune tolerance. Several novel therapeutic targets are being investigated; these include inhibitors of the B-cell receptor signaling pathways, the PI3K/mTOR/Akt pathway, histone deacetylases, BCL-2, the proteasome, PD-1 and PD-L1, and the tumor immune microenvironment [4]. Many of the new agents show excellent toxicity profiles, and combining these novel therapies may result in a higher quality of response and potentially significant improvement in survival outcomes for NHL patients [4-6].
Advances are being made in understanding how non-cytotoxic agents act against various B-cell malignancies. Progress in unraveling the underlying biology is setting the stage for the development of novel treatment paradigms with the aim of improving on current standards of care. New treatment paradigms will have to address how novel agents can be integrated into existing modalities. In short, the increased number of potential therapeutic options warrants the need to re-evaluate the utility of current treatment guidelines and clinical endpoints in relation to the optimization of patient outcomes.
Thursday, June 18, from 19:00 to 21:00 (room B)
MUNDIPHARMA ONCOLOGY
CLL AND FOLLICULAR NHL: CRITICAL REVIEW OF THE CURRENT GUIDELINES AND FUTURE PERSPECTIVES
Co-chairs: J.G. Gribben, London (UK) and M. Ghielmini, Bellinzona (Switzerland)
GERMAN PRACTICES IN CLL
C. Wendtner, Munich (Germany)
FRENCH PRACTICES IN CLL
O. Tournilhac, Clermont Ferrand (France)
UK PRACTICES IN FOLLICULAR NHL
A. Davies, Southampton (UK)
SWISS PRACTICES IN FOLLICULAR NHL
M. Ghielmini, Bellinzona (Switzerland)
Friday, June 19, from 18:45 to 19:45 (room A)
ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND—IOSI
Supported by an unrestricted educational grant by GILEAD SCIENCES EUROPE, LTD.
THE BIG DEBATE: SHOULD WE ALWAYS AIM AT MINIMAL RESIDUAL DISEASE ERADICATION?
Chair: M. Ghielmini, Bellinzona (Switzerland)
CLL—YES: J.G. Gribben, London (UK) vs —NO: S. Stilgenbauer, Ulm (Germany)
MCL—YES: M. Dreyling, Munich (Germany) vs —NO: J.P. Leonard, New York, NY (USA)
MM—YES: M. Cavo, Bologna (Italy) vs —NO: S.V. Rajkumar, Rochester, MN (USA)
1099-1069/asset/olalertbanner.jpg?v=1&s=5a2e5e22ad4ef4d48186ee37f977bc7094efd01d)